Sarah Sharon Gabriel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sarah Sharon Gabriel has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Axel Kallies
Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
10 shared publications - Kevin Man
Department of Microbiology and Immunology, University of Melbourne, Melbourne, Victoria, Australia
3 shared publications Wei Shi
Olivia Newton-John Cancer Research Institute, Heidelberg, Australia
3 shared publicationsAndrew Bushell
Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford , Oxford , UK
2 shared publications- Carlson Tsui
Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity University of Melbourne Melbourne VIC Australia
2 shared publications - Chun-Hsi Su
Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
2 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2121-2134
Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland
1. Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies including cancers of the oral cavity, oropharynx, hypopharynx, and larynx.1 Worldwide, HNSCC is the seventh most common c...
- 7 August 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2121-2134
Open AccessCost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland
1. Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies including cancers of the oral cavity, oropharynx, hypopharynx, and larynx.1 Worldwide, HNSCC is the seventh most common c...
- 31 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eadw1992
Stem-like tissue-resident memory T cells control functional heterogeneity and reactivation of T cell memory in the intestine
Tissue-resident memory T (T RM ) cells provide localized immunity against intracellular pathogens and cancer. Upon antigen reencounter, T RM cells differentiate into effector cells while also giving rise to another generation of memory cells. Here, we show that intestinal T RM cells that express the transcriptional regulators TCF1 or ID3 exhibit stem-like memory properties and are endowed with a superior capacity to regenerate effector and memory T cells after pathogen reencounter. Ablation of TCF1 using a T RM cell–specific mouse model resulted in impaired formation of intestinal T RM cells, altered their transcriptional heterogeneity, and increased their differentiation into tissue-confined and recirculating CX3CR1 + effector cells during recall. TGF-β and retinoic acid were required for formation and survival of TCF1- and ID3-expressing T RM cells and restrained their differentiation into CX3CR1 + effector cells during reinfection. Thus, stem-like cells control the quality and recall capacity of T RM cells, thereby contributing to anamnestic memory responses.
- 31 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eadw1992
Stem-like tissue-resident memory T cells control functional heterogeneity and reactivation of T cell memory in the intestine
Tissue-resident memory T (T RM ) cells provide localized immunity against intracellular pathogens and cancer. Upon antigen reencounter, T RM cells differentiate into effector cells while also giving rise to another generation of memory cells. Here, we show that intestinal T RM cells that express the transcriptional regulators TCF1 or ID3 exhibit stem-like memory properties and are endowed with a superior capacity to regenerate effector and memory T cells after pathogen reencounter. Ablation of TCF1 using a T RM cell–specific mouse model resulted in impaired formation of intestinal T RM cells, altered their transcriptional heterogeneity, and increased their differentiation into tissue-confined and recirculating CX3CR1 + effector cells during recall. TGF-β and retinoic acid were required for formation and survival of TCF1- and ID3-expressing T RM cells and restrained their differentiation into CX3CR1 + effector cells during reinfection. Thus, stem-like cells control the quality and recall capacity of T RM cells, thereby contributing to anamnestic memory responses.
- Top Cited Papers
- 29 July 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (8) , 1367-1383
Lymph-node-derived stem-like but not tumor-tissue-resident CD8+ T cells fuel anticancer immunity
CD8+ T cell-mediated tumor control and efficacy of immune checkpoint blockade (ICB) are associated with both precursors of exhausted T (TPEX) cells and tissue-resident memory T cells. Their relationships and relative contribution to tumor control, however, are insufficiently understood. Using single-cell RNA sequencing and genetic mouse models, we systematically dissected the heterogeneity and function of cytotoxic T cells in tumors and tumor-draining lymph nodes (tdLNs). We found that intratumoral TCF1+ TPEX cells and their progeny acquired a tissue-residency program that limits their contribution to tumor control and ICB response. By contrast, MYB-dependent stem-like TPEX cells residing in tdLNs sustained CD8+ T cell infiltration into tumors and mediated ICB response. The cytokine TGFβ was the central factor that enforced residency of intratumoral CD8+ T cells and limited the abundance of stem-like TPEX cells in tdLNs, thereby restraining tumor control. A similar network of TGFβ-constrained intratumoral and extratumoral CD8+ T cells with precursor and residency characteristics was found in human cancer.
- 29 July 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (8) , 1367-1383
Top Cited PapersLymph-node-derived stem-like but not tumor-tissue-resident CD8+ T cells fuel anticancer immunity
CD8+ T cell-mediated tumor control and efficacy of immune checkpoint blockade (ICB) are associated with both precursors of exhausted T (TPEX) cells and tissue-resident memory T cells. Their relationships and relative contribution to tumor control, however, are insufficiently understood. Using single-cell RNA sequencing and genetic mouse models, we systematically dissected the heterogeneity and function of cytotoxic T cells in tumors and tumor-draining lymph nodes (tdLNs). We found that intratumoral TCF1+ TPEX cells and their progeny acquired a tissue-residency program that limits their contribution to tumor control and ICB response. By contrast, MYB-dependent stem-like TPEX cells residing in tdLNs sustained CD8+ T cell infiltration into tumors and mediated ICB response. The cytokine TGFβ was the central factor that enforced residency of intratumoral CD8+ T cells and limited the abundance of stem-like TPEX cells in tdLNs, thereby restraining tumor control. A similar network of TGFβ-constrained intratumoral and extratumoral CD8+ T cells with precursor and residency characteristics was found in human cancer.
- 31 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (103) , eadn1945
Stem-like memory and precursors of exhausted T cells share a common progenitor defined by ID3 expression
Stem-like T cells are attractive immunotherapeutic targets in patients with cancer given their ability to proliferate and differentiate into effector progeny. Thus, identifying T cells with enhanced stemness and understanding their developmental requirements are of broad clinical and therapeutic interest. Here, we demonstrate that during acute infection, the transcriptional regulator inhibitor of DNA binding 3 (ID3) identifies stem-like T cells that are uniquely adapted to generate precursors of exhausted T (Tpex) cells in response to chronic infection or cancer. Expression of ID3 itself enables Tpex cells to sustain T cell responses in chronic infection or cancer, whereas loss of ID3 results in impaired maintenance of CD8 T cell immunity. Furthermore, we demonstrate that interleukin-1 (IL-1) family members, including IL-36β and IL-18, promote the generation of ID3 + T cells that mediate superior tumor control. Overall, we identify ID3 as a common denominator of stem-like T cells in both acute and chronic infections that is specifically required to sustain T cell responses to chronic stimulation.
- 31 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (103) , eadn1945
Stem-like memory and precursors of exhausted T cells share a common progenitor defined by ID3 expression
Stem-like T cells are attractive immunotherapeutic targets in patients with cancer given their ability to proliferate and differentiate into effector progeny. Thus, identifying T cells with enhanced stemness and understanding their developmental requirements are of broad clinical and therapeutic interest. Here, we demonstrate that during acute infection, the transcriptional regulator inhibitor of DNA binding 3 (ID3) identifies stem-like T cells that are uniquely adapted to generate precursors of exhausted T (Tpex) cells in response to chronic infection or cancer. Expression of ID3 itself enables Tpex cells to sustain T cell responses in chronic infection or cancer, whereas loss of ID3 results in impaired maintenance of CD8 T cell immunity. Furthermore, we demonstrate that interleukin-1 (IL-1) family members, including IL-36β and IL-18, promote the generation of ID3 + T cells that mediate superior tumor control. Overall, we identify ID3 as a common denominator of stem-like T cells in both acute and chronic infections that is specifically required to sustain T cell responses to chronic stimulation.
- 15 May 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (6) , 979-990
CD4+ T cell calibration of antigen-presenting cells optimizes antiviral CD8+ T cell immunity
Antiviral CD8+ T cell immunity depends on the integration of various contextual cues, but how antigen-presenting cells (APCs) consolidate these signals for decoding by T cells remains unclear. Here, we describe gradual interferon-α/interferon-β (IFNα/β)-induced transcriptional adaptations that endow APCs with the capacity to rapidly activate the transcriptional regulators p65, IRF1 and FOS after CD4+ T cell-mediated CD40 stimulation. While these responses operate through broadly used signaling components, they induce a unique set of co-stimulatory molecules and soluble mediators that cannot be elicited by IFNα/β or CD40 alone. These responses are critical for the acquisition of antiviral CD8+ T cell effector function, and their activity in APCs from individuals infected with severe acute respiratory syndrome coronavirus 2 correlates with milder disease. These observations uncover a sequential integration process whereby APCs rely on CD4+ T cells to select the innate circuits that guide antiviral CD8+ T cell responses.
- 15 May 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (6) , 979-990
CD4+ T cell calibration of antigen-presenting cells optimizes antiviral CD8+ T cell immunity
Antiviral CD8+ T cell immunity depends on the integration of various contextual cues, but how antigen-presenting cells (APCs) consolidate these signals for decoding by T cells remains unclear. Here, we describe gradual interferon-α/interferon-β (IFNα/β)-induced transcriptional adaptations that endow APCs with the capacity to rapidly activate the transcriptional regulators p65, IRF1 and FOS after CD4+ T cell-mediated CD40 stimulation. While these responses operate through broadly used signaling components, they induce a unique set of co-stimulatory molecules and soluble mediators that cannot be elicited by IFNα/β or CD40 alone. These responses are critical for the acquisition of antiviral CD8+ T cell effector function, and their activity in APCs from individuals infected with severe acute respiratory syndrome coronavirus 2 correlates with milder disease. These observations uncover a sequential integration process whereby APCs rely on CD4+ T cells to select the innate circuits that guide antiviral CD8+ T cell responses.
- Open Access
- 20 May 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (20) , 2721-2735
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation status. Indeed, targeting BCL-2 has produced clinically relevant responses in blood cancers with aberrant TP-53. However, in our study, TP53-mutated or -deficient myeloid and lymphoid leukemias outcompeted isogenic controls with intact TP-53, unless sufficient concentrations of BH3-mimetics targeting BCL-2 or MCL-1 were applied. Strikingly, tumor cells with TP-53 dysfunction escaped and thrived over time if inhibition of BCL-2 or MCL-1 was sublethal, in part because of an increased threshold for BAX/BAK activation in these cells. Our study revealed the key role of TP-53 in shaping long-term responses to BH3-mimetic drugs and reconciled the disparate pattern of initial clinical response to venetoclax, followed by subsequent treatment failure among patients with TP53-mutant chronic lymphocytic leukemia or acute myeloid leukemia. In contrast to BH3-mimetics targeting just BCL-2 or MCL-1 at doses that are individually sublethal, a combined BH3-mimetic approach targeting both prosurvival proteins enhanced lethality and durably suppressed the leukemia burden, regardless of TP53 mutation status. Our findings highlight the importance of using sufficiently lethal treatment strategies to maximize outcomes of patients with TP53-mutant disease. In addition, our findings caution against use of sublethal BH3-mimetic drug regimens that may enhance the risk of disease progression driven by emergent TP53-mutant clones.
- 20 May 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (20) , 2721-2735
Open AccessIntact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation status. Indeed, targeting BCL-2 has produced clinically relevant responses in blood cancers with aberrant TP-53. However, in our study, TP53-mutated or -deficient myeloid and lymphoid leukemias outcompeted isogenic controls with intact TP-53, unless sufficient concentrations of BH3-mimetics targeting BCL-2 or MCL-1 were applied. Strikingly, tumor cells with TP-53 dysfunction escaped and thrived over time if inhibition of BCL-2 or MCL-1 was sublethal, in part because of an increased threshold for BAX/BAK activation in these cells. Our study revealed the key role of TP-53 in shaping long-term responses to BH3-mimetic drugs and reconciled the disparate pattern of initial clinical response to venetoclax, followed by subsequent treatment failure among patients with TP53-mutant chronic lymphocytic leukemia or acute myeloid leukemia. In contrast to BH3-mimetics targeting just BCL-2 or MCL-1 at doses that are individually sublethal, a combined BH3-mimetic approach targeting both prosurvival proteins enhanced lethality and durably suppressed the leukemia burden, regardless of TP53 mutation status. Our findings highlight the importance of using sufficiently lethal treatment strategies to maximize outcomes of patients with TP53-mutant disease. In addition, our findings caution against use of sublethal BH3-mimetic drug regimens that may enhance the risk of disease progression driven by emergent TP53-mutant clones.
- Open Access
- 1 November 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (9) , 2634-2645.e5
IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis
- 1 November 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (9) , 2634-2645.e5
Open AccessIRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis
- Open Access
- 15 March 2019
- Published by Springer Nature in Cell Research
- Vol. 29 (5) , 341-342
Tissue-resident memory T cells keep cancer dormant
- 15 March 2019
- Published by Springer Nature in Cell Research
- Vol. 29 (5) , 341-342
Open AccessTissue-resident memory T cells keep cancer dormant
- Top Cited Papers
Transcription Factor IRF4 Promotes CD8+ T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection
- 1 April 2017
- Published by Elsevier in Kidney International
- Vol. 91 (4) , 842-855
Bone marrow transplantation improves proximal tubule dysfunction in a mouse model of Dent disease
- 1 April 2017
- Published by Elsevier in Kidney International
- Vol. 91 (4) , 842-855
Bone marrow transplantation improves proximal tubule dysfunction in a mouse model of Dent disease